CS Paper Radar

Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables

Pablo García Marcos, Paula Puerta González, Guillermo Lorenzo, Héctor Gómez, Covadonga del Camino, Adán Rodríguez, Ignacio Peláez, Angel Rio-Alvarez, Víctor M. González

cs.AI cs.CV ·submitted 2026-08-18 11:52 UTC · v1

Abstract

Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients. This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables. The study uses the public ACRIN 6698/I-SPY2 multicenter dataset. The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information. Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter. Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model. Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74. Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively. The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86. These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.

Closest papers

Nearest neighbours by meaning across the whole index.

Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy Using Temporal Deep Learning on DWI

cs.AI ·2026-08-18 ·Pablo García Marcos, Md. Tarequl Islam, Paula Puerta González, Guillermo Lorenzo, Héctor Gómez +3 more
similarity 0.80
Abstract

Early identification of non-responders to neoadjuvant chemotherapy (NACT) is crucial for timely treatment adaptation in breast cancer. However, many existing predictive models rely on multiparametric magnetic resonance imaging (MRI), late treatment time points, or extensive clinical data, which limits their applicability. This study proposes a deep learning framework for early prediction of pathological complete response (pCR) using only diffusion-weighted MRI (DW-MRI) acquired at baseline and after the first NACT cycle. This framework feeds cropped tumor-centered patches to an EfficientNet-based temporal model that directly learns tumor shape and local tissue characteristics without explicit radiomic feature engineering. The model, trained with 10-fold cross-validation, achieved an area under the receiver operating characteristic curve (AUC) of 0.90 for pCR prediction after one cycle, providing actionable information after a single treatment cycle while avoiding gadolinium administration and reducing dependence on heterogeneous clinical data. By focusing on the baseline-to-first-cycle window instead of later stages, the approach supports earlier escalation or de-escalation of NACT, and its exclusive reliance on DW-MRI facilitates protocol standardization, multi-centre deployment and privacy-preserving data sharing. These results demonstrate that DW-MRI-based deep learning on tumor-centered patches constitutes a minimally invasive, clinically deployable strategy for early pCR prediction, with direct implications for personalized treatment adaptation in neoadjuvant breast cancer therapy.

0.21

Deep Learning-Based Prediction of HER2 Status from Whole-Brain MRI in Breast Cancer Brain Metastases

cs.LG ·2026-10-23 ·Sara Early, Chris Kang, Vibujithan Vigneshwaran, Kimberly Amador, Roger Y. Tsang +1 more
similarity 0.72
Abstract

Purpose: Human epidermal growth factor receptor 2 (HER2) status is a key biomarker relevant for prognostication and treatment decision making in metastatic breast cancer. Thus, the aim of this work was to explore whether HER2 status can be predicted directly from whole-brain post-contrast T1-weighted (T1w) MRI scans in breast cancer brain metastases (BCBM) using deep learning, and whether providing explicit tumour segmentation information improves prediction. Methods: Using the publicly available BCBM-Radiogenomics dataset, we analysed 135 patients, including 70 HER2+ and 65 HER2- patients. Three approaches were implemented and evaluated: a conventional radiomics model, a simple fully convolutional network (SFCN) using T1w MRI scans alone, and an SFCN using T1w MRI scans with an expert-derived tumour mask as an additional input channel. Results: The radiomics model achieved an area under the receiver operating characteristic curve (ROC-AUC) of 0.602 (95% confidence interval [CI]: 0.528--0.677) while the SFCN achieved a ROC-AUC of 0.667 (95% CI, 0.63--0.71) using T1w MRI scans alone, which increased to 0.692 (95% CI, 0.58--0.81) when an explicit tumour mask was additionally provided. Conclusion: However, the modest performance across all approaches demonstrates the difficulty of predicting HER2 status from structural MRI scans alone. The difference between the segmentation-free and mask-guided SFCN models suggests that much of the predictive signal captured by the deep-learning model may be learned directly from whole-brain T1w MRI without requiring explicit tumour delineation. These findings support further investigation of segmentation-free deep-learning approaches as a potential non-invasive strategy to support HER2 status determination in BCBM.

0.19

CoRe-WM: Conditioned Response-State World Modeling for Longitudinal Treatment-Response Prediction in Breast DCE-MRI

cs.CV ·2026-10-18 ·Lin Zhao, Bowen Chen, Qiaohui Gao, Shaowen Wan, Xiang Li +2 more
similarity 0.70
Abstract

Pathologic complete response (pCR) after neoadjuvant chemotherapy is a key prognostic indicator in aggressive breast cancer, yet existing prediction approaches either rely on pretreatment imaging alone, missing the patient's evolving response, or optimize multi-visit classifiers under direct outcome supervision, coupling representation learning with the clinical endpoint. We formulate longitudinal pCR prediction as a world-modeling problem and propose Conditioned Response-state World Modeling (CoRe-WM), which learns a latent state-transition model that predicts the next imaging state from the observed sequence. The transition function is conditioned on patient clinical profile and assigned therapy through additive shift and feature-wise modulation, enabling patient- and treatment-specific dynamics. A Factorized Response State pathway further decouples treatment-response dynamics from imaging appearance by encoding the structural prior that response manifests primarily in lesion morphology. After pretraining, all parameters are frozen and a linear readout predicts pCR at each clinical decision point. We evaluate CoRe-WM on I-SPY2 under five-fold cross-validation and assess cross-cohort transfer on I-SPY1. CoRe-WM achieves the highest discrimination among all evaluated methods at every prospective decision point, and demonstrates robust cross-cohort transfer. Ablation studies identify patient-profile conditioning and the factorized response pathway as the principal contributors. These results establish world-model-based representation learning as a promising framework for outcome prediction in oncology and beyond.

0.20

Interpretable Deep Learning Models for Breast Cancer Diagnosis Using Medical Imaging

cs.CV cs.AI ·2026-10-27 ·Sami Alnawali, Muhammad Atif Saeed, Abdul Hadi, Azka Atiq, Akhtar Jamil +1 more
benchmark similarity 0.69
Abstract · 37 page, 45 Figures

Deep learning shows promise for breast cancer diagnosis, but limited interpretability hinders clinical adoption. We benchmark ten ImageNet-pretrained models (ResNet50, VGG19, InceptionV3, DenseNet121, Xception, MobileNetV2, EfficientNet, ConvNeXt, ViT, and Swin Transformer) for benign-versus-malignant classification on the BreakHis histopathology dataset using a patient-level split, and explain their predictions with Grad-CAM, LIME, Integrated Gradients, and LRP. DenseNet121 performed best, with 99.4% test accuracy and an AUC-ROC of 0.999, and significantly outperformed all other models (p < 0.001). Transformer-based models trailed the CNNs. The explanations consistently highlighted nuclei-rich and glandular regions of diagnostic relevance. Combining transfer learning with explainable AI can thus yield accurate, interpretable tools for breast cancer diagnosis.

0.19

Mammo-LIFE: Longitudinal Mammographic Imaging and Clinical Feature Enrichment for Post-Radiotherapy Outcome Prediction

cs.CV eess.IV ·2026-09-22 ·Farnoush Bayatmakou, Maryam Hosseini, Reza Taleei, Arash Mohammadi
similarity 0.68
Abstract

Recent advances in Artificial Intelligence (AI)-powered Computer-Aided Diagnosis (CAD) systems have substantially improved breast cancer screening, diagnosis, and prognosis. Comparatively, postradiotherapy outcome prediction using paired longitudinal mammograms has received considerably less attention. This is largely due to the limited availability of well-annotated longitudinal datasets. Longitudinal mammograms, coupled with paired pre- and post-treatment information, provide a unique opportunity to characterize treatment-induced breast tissue changes following radiotherapy. The resulting learned representations can serve as a valuable asset for advancing personalized radiotherapy planning and post-treatment management. In this context, we propose Mammo-LIFE, a patient-level multimodal framework for post-radiotherapy outcome prediction that combines longitudinal mammographic features with patient-level clinical variables. The imaging branch processes paired pre- and post-treatment mammograms acquired from the four standard views using a mammography-specific encoder adapted via Low-Rank Adaptation (LoRA). Within each view, preand post-treatment representations are explicitly compared through a longitudinal comparison module to capture treatment-related changes. The resulting view-level embeddings are then aggregated using learned view-attention pooling to form a unified patient-level mammographic representation. Selected clinical variables are subsequently combined with the image-derived prediction probability through a late-fusion strategy. To evaluate the effectiveness of combining paired longitudinal mammograms with clinical information, experiments were conducted on an in-house clinical cohort using patient-level stratified five-fold cross-validation.

0.26

Evaluating ADC-only deep learning pipelines for breast cancer detection and segmentation using standalone diffusion-weighted MRI

cs.CV cs.AI ·2026-08-18 ·Pablo García Marcos, Paula Puerta Gonzĺez, Guillermo Lorenzo, Héctor Gómez, Covadonga del Camino +2 more
similarity 0.67
Abstract

Dynamic contrast-enhanced (DCE) imaging is the gold standard technique for the detection and characterization of breast cancer using magnetic resonance imaging (MRI). However, DCE-MRI requires long acquisition times and the administration of contrast into the bloodstream, which can cause allergic reactions. Alternatively, diffusion-weighted MRI (DW-MRI) is a standard complementary technique for breast MRI that does not require contrast, has shorter acquisition times, and enables calculation of apparent diffusion coefficient (ADC) maps that correlate with tumor cellularity. Yet, despite these technical advantages, deep learning research has focused on DCE-based models and has barely explored the tumor detection performance of DW-MRI and ADC maps either in combination with DCE-MRI or as standalone alternatives. Here, we evaluate the application of different state-of-the-art deep learning techniques for detection and segmentation of breast cancer using ADC-only images. This is, to our knowledge, the first comprehensive evaluation of ADC-only breast cancer pipelines for classification, detection, and segmentation tasks.

0.26

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.65
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06

SideAge-RiskNet: Predicted Mammographic-Age Features for Future Breast Cancer Risk and Laterality Prediction

eess.IV ·2026-11-04 ·Haoyan Ding, Encheng Su, Chaowei Wu, Lixia Wang, Qian Wang +4 more
similarity 0.64
Abstract · 5 pages, 2 figures

Whether breast-specific mammographic aging provides information beyond chronological age for future cancer prediction remains unclear. We propose SideAge-RiskNet, a framework integrating predicted mammographic-age features with breast-specific representations for multi-year breast cancer risk and conditional laterality prediction. A side-aware DenseNet121 trained on never-cancer reference examinations estimates left and right breast ages. Age-adjusted residuals and bilateral age descriptors are subsequently fused with corresponding image representations, while clinical variables contribute through an image--clinical risk branch. The framework jointly predicts cumulative cancer risk over 1--5 years and the subsequently affected breast among unilateral cancer cases. Across 4,480 EMBED and 248 external examinations, pre-cancer scans demonstrated pronounced bilateral age asymmetry. SideAge-RiskNet established state-of-the-art performance in 1--5-year risk assessment over Mirai and AsymMirai with mean risk AUROCs of 81.73% on EMBED and 72.83% on CSMC. Furthermore, it enabled conditional cancer laterality prediction, achieving AUROCs of 73.26% and 82.53%, respectively. This demonstrates the critical utility of bilateral aging phenotypes in localized breast cancer risk surveillance.

0.20